Table 3.
Cisplatin-Nanoparticle Combinations Under Clinical Trials
| Name (Company) | Formulation | ClinicalTrials.gov Identifier | Status | Cancer Type |
|---|---|---|---|---|
| Lipoplatin (Regulon, Inc) | PEG- liposome-based | NCT02702700 | Phase 1 | Pleural Malignancies |
| SPI-77 (ALZA Pharmaceuticals) | PEG- liposome-based | NCT00004083 | Phase II Pilot | Ovarian Cancer |
| NCT00102531 | Phase Ib/IIa | Osteosarcoma Metastatic to the Lung | ||
| NCT00004033 | Phase II | Malignant Pleural Mesothelioma | ||
| NCT01861496 | Phase I/II | Advanced or Refractory Tumours | ||
| NC-6004 Nanoplatin (NanoCarrier Co., Ltd) | Polymeric -Micelles | NCT00910741 | Phase I/II | Pancreatic Cancer |
| AroplatinTM (Aronex Pharmaceuticals) | Liposomes | NCT00316511 | Phase 1 | B-Cell Lymphoma |
| NCT00081536 | Phase I/II | Colorectal Cancer | ||
| NCT00081549 | Phase I/II | Metastatic Pancreatic Cancer | ||
| NCT00043199 | Phase II | Colorectal Cancer | ||
| NCT00057395 | Phase I/II | Solid Malignancies | ||
| NCT00004033 | Phase II | Malignant Pleural Mesothelioma | ||
| LiPlaCis (LiPlasome Pharma) | Liposome Based | NCT01861496 | Phase I/II | Advanced or Refractory Tumours |